CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen ; volume:12 ; number:4 ; day:23 ; month:8 ; year:2010 ; pages:1-11 ; date:8.2010
Breast cancer research ; 12, Heft 4 (23.8.2010), 1-11, 8.2010
- Urheber
-
Abraham, Jean E.
- Beteiligte Personen und Organisationen
-
Maranian, Mel J.
Driver, Kristy E.
Platte, Radka
Kalmyrzaev, Bolot
Baynes, Caroline
Luccarini, Craig
Shah, Mitul
Ingle, Susan
Greenberg, David
Earl, Helena M.
Dunning, Alison M.
Pharoah, Paul DP
Caldas, Carlos
SpringerLink (Online service)
- DOI
-
10.1186/bcr2629
- URN
-
urn:nbn:de:1111-201603248237
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Abraham, Jean E.
- Maranian, Mel J.
- Driver, Kristy E.
- Platte, Radka
- Kalmyrzaev, Bolot
- Baynes, Caroline
- Luccarini, Craig
- Shah, Mitul
- Ingle, Susan
- Greenberg, David
- Earl, Helena M.
- Dunning, Alison M.
- Pharoah, Paul DP
- Caldas, Carlos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
Sox2 promotes tamoxifen resistance in breast cancer cells
A candidate molecular signature associated with tamoxifen failure in primary breast cancer
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer
Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
Sox2 promotes tamoxifen resistance in breast cancer cells
A candidate molecular signature associated with tamoxifen failure in primary breast cancer
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer
Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
Sox2 promotes tamoxifen resistance in breast cancer cells
A candidate molecular signature associated with tamoxifen failure in primary breast cancer
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer